Takara Bio Licenses FLT3 Gene Mutation Detection Method to InVivoScribe Technologies.Tokyo, Japan, July 12, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takara Bio has entered into a licensing agreement with US company InVivoScribe Technologies for a patent on detecting the mutations of FMS-like tyrosine kinase tyrosine kinase An enzyme intimately linked to signal transduction–ST, either as a receptor-type TK, which participates in transmembrane signaling, or as an intracellular TK, participating in ST to the nucleus; ↑ or ↓ TK activity is associated with 3 (FLT FLT Fault FLT Flight FLT Flat FLT Filter FLT Fleet FLT Fermat's Last Theorem FLT Fairlight (software cracking group) FLT Float/Floating FLT Fairfield Language Technologies FLT Fork Lift Truck FLT First Lieutenant 3) genes developed by Takara Bio. Under the agreement, InVivoScribe Technologies will receive an exclusive license to use the patent worldwide, except in Japan, including the development, manufacture and sales of a reagent for detecting FLT3 gene mutations. Further, the US company can sublicense the patent to other gene test makers and medical laboratories. InVivoScribe Technologies will make an upfront payment and royalties on sales and sublicenses to Takara Bio. FLT3 is an acceptor acceptor - Finite State Machine protein that plays a crucial role in early hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. regulation. FLT3 is considered to be one of the major causes of acute myeloid leukemia. Currently, Takara Bio is obtaining a patent on the detection method of FLT3 gene mutations in Japan and the US and has filed a patent application in Europe. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion